How can we monitor Dabigatran effects ? Dabigatran, like argatroban, does prolong the prothrombin time (PT) and partial thromboplastin time (PTT). It also prolongs the thrombin time (TT), which means it generates a false decrease in fibrinogen assay results, given that the fibrinogen assay is based on the TT. Dabigatran’s plasma concentration peaks about two […]
The Dabigatran revolution is soon to come attached the Giacalone 2011 comment letter from our group.
From Louisiana a new survey on dabigatran published on circulation in january : Dabigatran is a reasonable alternative to warfarin in patients requiring cardioversion.
Current Issue Volume 9, Issue 12 (December, 2010) Issue Contents: (Pages 1139-1232) Because of the necessary trade-off between stroke prevention and bleeding with both doses of dabigatran, consultation with patients regarding their preferences for treatment dose will be even more important to ascertain their threshold for stroke prevention over increased bleeding risk or vice versa.
The Italian guidelines for stroke SPREAD (sponsored by Bayer health care) reported dabigatran as a safe alternative to warfarin. This is a sort of vital validation for the molecule since almost nothing can be done in stroke medicine without the SPREAD committee approval at a national level. At a national level also the Mario Negri […]
From Manchester (UK) a meta-analysis reporting how dabigatran may be more effective than aspirin/placebo in reducing risk of stroke, systemic embolization and mortality in AF… see on Thrombosis anf Haemostasis Oct issue
Recently reported the first case of ischemic stroke succesfully treated with endovenous thrombolysis during dabigatran treatment. The patients was included in the RELY trial and suffered of a severe ischemic stroke with an NIH stroke scale of 19. He successfully recovered after the rTPA infusion within 3 hours from onset according to the SITS ISTR standards. […]
on 30 August 2010 Ingelheim, Germany – Report: The European Society of Cardiology (ESC) today issued a revised version of guidelines for the management of atrial fibrillation (AF), including guidance on the role of thge new oral treatment, dabigatran etexilate, for the prevention of embolism in patients with atrial fibrillation (AF). At the same time, […]
strokefocus 